EU Approves Bristol Myers Squibb's Opdivo for Frontline Advanced Hodgkin Lymphoma
Reported by Reuters
Sentiment
Positive
Importance
8
Price
$57.16
Mkt Cap
$116.766B
52W Low
$42.52
52W High
$62.886
Market data snapshot near publication time
Summary
Bristol Myers Squibb's Opdivo, in combination with AVD, has received expanded EU label approval for frontline advanced classical Hodgkin Lymphoma. This regulatory win broadens the market for a key oncology drug, allowing it to be used earlier in treatment for a serious condition. This follows a series of positive drug development announcements for the company, including recent trial results for mezigdomide and Camzyos.
At the time of this announcement, BMY was trading at $57.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $116.8B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.
Price Chart
BMY - Latest Insights
BMY
Jun 01, 2026, 7:27 AM EDT
BMY
May 30, 2026, 3:13 AM EDT
BMY
May 29, 2026, 8:00 AM EDT
BMY
May 20, 2026, 7:08 AM EDT
BMY
May 12, 2026, 12:17 AM EDT
BMY
May 01, 2026, 4:05 PM EDT
BMY
Apr 30, 2026, 11:44 AM EDT
BMY
Apr 30, 2026, 7:14 AM EDT
BMY
Apr 30, 2026, 7:01 AM EDT
BMY
Mar 29, 2026, 11:47 AM EDT